Transthyretin sequesters amyloid beta protein and prevents amyloid formation.

Schwarzman, A L; Gregori, L; Vitek, M P; Lyubski, S; Strittmatter, W J; Enghilde, J J; Bhasin, R; Silverman, J et al. · Proc Natl Acad Sci U S A · 1994

basic_science · Level V

Where this comes from

Abstract

The cardinal pathological features of Alzheimer disease are depositions of aggregated amyloid beta protein (A beta) in the brain and cerebrovasculature. However, the A beta is found in a soluble form in cerebrospinal fluid in healthy individuals and patients with Alzheimer disease. We postulate that sequestration of A beta precludes amyloid formation. Failure to sequester A beta in Alzheimer disease may result in amyloidosis. When we added A beta to cerebrospinal fluid of patients and controls it was rapidly sequestered into stable complexes with transthyretin. Complexes with apolipoprotein E, which has been shown to bind A beta in vitro, were not observed in cerebrospinal fluid. Additional in vitro studies showed that both purified transthyretin and apolipoprotein E prevent amyloid formation.

Medical subject headings